Cancer Research Donn Young  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cripe, T. P.
Right arrow Articles by Currier, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cripe, T. P.
Right arrow Articles by Currier, M. A.
[Cancer Research 61, 2953-2960, April 1, 2001]
© 2001 American Association for Cancer Research


Experimental Therapeutics

Fiber Knob Modifications Overcome Low, Heterogeneous Expression of the Coxsackievirus-Adenovirus Receptor That Limits Adenovirus Gene Transfer and Oncolysis for Human Rhabdomyosarcoma Cells1

Timothy P. Cripe2, Edward J. Dunphy, Alison D. Holub, Arvind Saini, Neeti H. Vasi, Yoni Y. Mahller, Margaret H. Collins, Jean D. Snyder, Victor Krasnykh, David T. Curiel, Thomas J. Wickham, James DeGregori, Jeffrey M. Bergelson and Mark A. Currier

Division of Hematology/Oncology [T. P. C., N. H. V., Y. Y. M., M. A. C.] and Department of Pathology [M. H. C., J. D. S.], Children’s Hospital Medical Center, Cincinnati, Ohio 45229; Division of Pediatric Hematology/Oncology, University of Wisconsin Children’s Hospital and Comprehensive Cancer Center, Madison, Wisconsin 53792 [E. J. D., A. D. H., A. S.]; University of Alabama, Birmingham, Alabama 35294 [V. K., D. T. C.]; Research and Development, GenVec Inc., Gaithersburg, Maryland 20879 [T. J. W.]; University of Colorado Health Sciences Center, Denver, Colorado 80262 [J. D.]; and Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 [J. M. B.]

Exploiting the lytic life cycle of viruses has gained recent attention as an anticancer strategy (oncolysis). To explore the utility of adenovirus (Ad)-mediated oncolysis for rhabdomyosarcoma (RMS), we tested RMS cell lines for Ad gene transduction and infection. RMS cells were variably transduced by Ad. Compared with control cells, RMS cells were less sensitive or even resistant to oncolysis by wild-type virus. RMS cells expressed the Ad internalization receptors, {alpha}v integrins, but had low or undetectable expression of the major attachment receptor, coxsackievirus-Ad receptor (CAR). Mutant Ads with ablated CAR binding exhibited only 5–20% of transgene expression in RMS cells seen with a wild-type vector, suggesting that residual or heterogeneous CAR expression mediated the little transduction that was detectable. Immunohistochemical analysis of archived clinical specimens showed little detectable CAR expression in five embryonal and eight alveolar RMS tumors. Stable transduction of the cDNA for CAR enabled both efficient Ad gene transfer and oncolysis for otherwise resistant RMS cells, suggesting that poor CAR expression is the limiting feature. Gene transfer to RMS cells was increased >2 logs using Ads engineered with modified fiber knobs containing either an integrin-binding RGD peptide or a polylysine peptide in the exposed HI loop. The RGD modification enabled increased oncolysis for RMS cells by a conditionally replicative Ad, Ad{Delta}24RGD, harboring a retinoblastoma-binding mutation in the E1A gene. Thus, the development of replication-competent vectors targeted to cell surface receptors other than CAR is critical to advance the use of Ad for treating RMS.




This article has been cited by other articles:


Home page
Cancer Res.Home page
H.-J. Li, M. Everts, M. Yamamoto, D. T. Curiel, and H. R. Herschman
Combined Transductional Untargeting/Retargeting and Transcriptional Restriction Enhances Adenovirus Gene Targeting and Therapy for Hepatic Colorectal Cancer Tumors
Cancer Res., January 15, 2009; 69(2): 554 - 564.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Tsuruta, L. Pereboeva, M. Breidenbach, D. T. Rein, M. Wang, R. D. Alvarez, G. P. Siegal, P. Dent, P. B. Fisher, and D. T. Curiel
A Fiber-Modified Mesothelin Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer
Clin. Cancer Res., June 1, 2008; 14(11): 3582 - 3588.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M.H. Hassan, N. Khatoon, D.T. Curiel, F.M. Hamada, H.M. Arafa, and A. Al-Hendy
Toward gene therapy of uterine fibroids: targeting modified adenovirus to human leiomyoma cells
Hum. Reprod., March 1, 2008; 23(3): 514 - 524.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Tsuruta, L. Pereboeva, J. N. Glasgow, D. T. Rein, Y. Kawakami, R. D. Alvarez, R. P. Rocconi, G. P. Siegal, P. Dent, P. B. Fisher, et al.
A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus {sigma}1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor Independent Pathway
Clin. Cancer Res., May 1, 2007; 13(9): 2777 - 2783.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Gomez-Manzano, M. M. Alonso, W.K. A. Yung, F. McCormick, D. T. Curiel, F. F. Lang, H. Jiang, B. N. Bekele, X. Zhou, R. Alemany, et al.
Delta-24 Increases the Expression and Activity of Topoisomerase I and Enhances the Antiglioma Effect of Irinotecan
Clin. Cancer Res., January 15, 2006; 12(2): 556 - 562.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
F. Kuhnel, B. Schulte, T. Wirth, N. Woller, S. Schafers, L. Zender, M. Manns, and S. Kubicka
Protein Transduction Domains Fused to Virus Receptors Improve Cellular Virus Uptake and Enhance Oncolysis by Tumor-Specific Replicating Vectors
J. Virol., December 15, 2004; 78(24): 13743 - 13754.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir
Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer
Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. Gomez-Manzano, W.K. A. Yung, R. Alemany, and J. Fueyo
Genetically modified adenoviruses against gliomas: From bench to bedside
Neurology, August 10, 2004; 63(3): 418 - 426.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. Gu, A. Ogose, H. Kawashima, M. Ito, T. Ito, A. Matsuba, H. Kitahara, T. Hotta, K. Tokunaga, H. Hatano, et al.
High-Level Expression of the Coxsackievirus and Adenovirus Receptor Messenger RNA in Osteosarcoma, Ewing's Sarcoma, and Benign Neurogenic Tumors among Musculoskeletal Tumors
Clin. Cancer Res., June 1, 2004; 10(11): 3831 - 3838.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Qin, S. Chen, T. Yu, B. Escuadro, S. Sharma, and R. K. Batra
Coxsackievirus Adenovirus Receptor Expression Predicts the Efficiency of Adenoviral Gene Transfer into Non-Small Cell Lung Cancer Xenografts
Clin. Cancer Res., October 15, 2003; 9(13): 4992 - 4999.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
O. Hamid, M. L. Varterasian, S. Wadler, J. R. Hecht, A. Benson III, E. Galanis, M. Uprichard, C. Omer, P. Bycott, R. C. Hackman, et al.
Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., April 15, 2003; 21(8): 1498 - 1504.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. W. Schoggins, J. G. D. Gall, and E. Falck-Pedersen
Subgroup B and F Fiber Chimeras Eliminate Normal Adenovirus Type 5 Vector Transduction In Vitro and In Vivo
J. Virol., December 20, 2002; 77(2): 1039 - 1048.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. S. Haviv, J. L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito, X. Lei, A. Hemminki, et al.
Adenoviral Gene Therapy for Renal Cancer Requires Retargeting to Alternative Cellular Receptors
Cancer Res., August 1, 2002; 62(15): 4273 - 4281.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. Hemminki, K. R. Zinn, B. Liu, T. R. Chaudhuri, R. A. Desmond, B. E. Rogers, M. N. Barnes, R. D. Alvarez, and D. T. Curiel
In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus
J Natl Cancer Inst, May 15, 2002; 94(10): 741 - 749.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
V. W. van Beusechem, J. Grill, D. C. J. Mastenbroek, T. J. Wickham, P. W. Roelvink, H. J. Haisma, M. L. M. Lamfers, C. M. F. Dirven, H. M. Pinedo, and W. R. Gerritsen
Efficient and Selective Gene Transfer into Primary Human Brain Tumors by Using Single-Chain Antibody-Targeted Adenoviral Vectors with Native Tropism Abolished
J. Virol., February 22, 2002; 76(6): 2753 - 2762.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. Kim, T. Smith, N. Idamakanti, K. Mulgrew, M. Kaloss, H. Kylefjord, P. C. Ryan, M. Kaleko, and S. C. Stevenson
Targeting Adenoviral Vectors by Using the Extracellular Domain of the Coxsackie-Adenovirus Receptor: Improved Potency via Trimerization
J. Virol., February 15, 2002; 76(4): 1892 - 1903.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.